← Leaderboards
Venkata M Reddy
University Of Illinois At Chicago
$4,643,906
Attributed
$4,643,906
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2006–10$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$4,643,906 · 5
By mechanism
R44$2,459,384 · 1
R21$1,143,360 · 1
R43$822,677 · 2
R29$218,485 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Christopher G Engeland$5,167,211
- Pavel A Petukhov$5,330,073
Others in their field
Top investigators on “Killings”
- Barton F Haynes · Duke University$127,170,432
- Douglas F Nixon · J. David Gladstone Institutes$28,355,657
- David Heimbrook · Leidos Biomedical Research, Inc.$26,054,235
- Michael R. Farzan · Boston Children'S Hospital$23,682,522
- William Robert Jacobs · Albert Einstein College Of Medicine$21,160,631
- David Alland · Rutgers Biomedical And Health Sciences$20,781,160
Research focus
KillingsBactericidePreclinical StudyTuberculosis DrugsMycobacterium TuberculosisIn VitroLungPharmaceutical PreparationsPropertyAntitubercular AgentsIn VivoGenus MycobacteriumMouse ModelMacrophageAntibioticsInfectionDoseGrantMulti-Drug ResistanceIsoniazidDrug StandardMutantDrug Resistance In TuberculosisMycobacterial
Grant awards (12)
Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugs$850,410
R44 · FY2010 · AI · contact PI
SQ641, new drug candidate to treat NTM infections$300,000
R43 · FY2010 · AI · contact PI
Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugs$795,701
R44 · FY2009 · AI · contact PI
Investigation of synergy between Rifampin and SQ109, a new anti-TB drug candidate$693,529
R21 · FY2009 · AI · contact PI
SQ641, new drug candidate to treat NTM infections$294,661
R43 · FY2009 · AI · contact PI
Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugs$19,372
R44 · FY2009 · AI · contact PI
Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugs$793,901
R44 · FY2008 · AI · contact PI
Investigation of synergy between Rifampin and SQ109, a new anti-TB drug candidate$202,331
R21 · FY2008 · AI · contact PI
Investigation of synergy between Rifampin and SQ109, a new anti-TB drug candidate$247,500
R21 · FY2007 · AI · contact PI
Novel mycobacterial translocase I inhibitors--a new class of anti-TB drugs$228,016
R43 · FY2006 · AI · contact PI
MOLECULAR MECHANISMS OF MAVIUM COMPLEX PATHOGENESIS$110,834
R29 · FY2001 · AI
MOLECULAR MECHANISMS OF MAVIUM COMPLEX PATHOGENESIS$107,651
R29 · FY2000 · AI